Latest / Glaucoma, Vision & Longevity: Supplements & Science / Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials

Transcript

Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Introduction.
• 0:00
  SPEAKER_00: Glaucoma is a chronic eye disease in which pressure buildup, intraocular pressure, or IOP, damages the optic nerve, leading to vision loss.
• 0:10
  SPEAKER_00: Standard treatments focus on lowering IOP by helping fluid drain out of the eye or reducing fluid production.
• 0:16
  SPEAKER_00: In 2026, several new clinical trials are testing novel approaches beyond the usual medications.
• 0:23
  SPEAKER_00: These include drugs and devices that enhance outflow, suppress inflow, prevent scarring, antifibrotics, protect the optic nerve, neuroprotective, and improve blood flow to the nerve, vascular modulators.
• 0:35
  SPEAKER_00: Each strategy has a clear laboratory rationale and often positive early human data.
• 0:40
  SPEAKER_00: For example, nitric oxide donating prostaglandins like NCX470 and rho kinase rock inhibitors aim to widen the trabecular meshwork or veins to enhance drainage.
• 0:51
  SPEAKER_00: Neuroprotective strategies such as high-dose vitamin B3 or GLP1 agonists have shown in animal models that they can preserve retinal nerve cells even without pressure changes.
• 1:02
  SPEAKER_00: Below we summarize each mechanism, its rationale, early evidence, and how trials measure success, e.g., IOP patterns, nerve imaging or visual fields, along with key safety issues.
• 1:15
  SPEAKER_00: Outflow enhancers.
• 1:17
  SPEAKER_00: What it is, these treatments aim to improve fluid drainage through the eye's natural outflow channels, trabecular meshwork and Schlem's canal, or add new paths.
• 1:26
  SPEAKER_00: Enhanced outflow lowers IOP without directly reducing fluid production.
• 1:30
  SPEAKER_00: Examples include new eyedrop drugs and microinvasive surgical devices.
• 1:36
  SPEAKER_00: Rationale, preclinical and early data.
• 1:38
  SPEAKER_00: Preclinical studies show that relaxing the trabecular meshwork or dilating outflow veins can dramatically increase fluid outflow.
• 1:46
  SPEAKER_00: For instance, rock inhibitors like netar sudal relax cellular tension in the drainage tissue.
• 1:51
  SPEAKER_00: In clinical trials, they lowered IOP as well as TMLO, a gold standard medicine.
• 1:57
  SPEAKER_00: Another example is QLS-111, an ATP-sensitive potassium channel opener that dilates veins and may reduce the downstream pressure on Schlem's canal.
• 2:06
  SPEAKER_00: In phase 2 human trials, QLS-111 added to Litanoprost dropped IOP by several memomer grams.
• 2:13
  SPEAKER_00: Device approaches, like suprachoroidal implants or laser trabeculoplasty, physically widen or reopen drainage channels, and early studies in animals and humans show pressure falls and improved outflow on imaging.
• 2:26
  SPEAKER_00: Earlier trial results.
• 2:28
  SPEAKER_00: A recent phase 3 study, NCX470, and others confirmed that combined outflow enhancers can beat traditional drops.
• 2:36
  SPEAKER_00: For example, NCX470, a bimataprost nitric oxide donor, lowered pressure more than Latanaprost at multiple time points in trials.
• 2:45
  SPEAKER_00: In summary, these agents demonstrated significant IOP reduction in controlled studies, supporting their mechanism of increasing outflow.
• 2:52
  SPEAKER_00: Primary endpoints.
• 2:54
  SPEAKER_00: Trials test the IOP lowering effect directly.
• 2:57
  SPEAKER_00: Typical primary endpoints include mean IOP reduction and diurnal 24-hour IOP profile.
• 3:02
  SPEAKER_00: For example, studies often measure IOP at 8 a.m., 10 a.m.
• 3:06
  SPEAKER_00: and 4 p.m.
• 3:07
  SPEAKER_00: on several follow-up visits.
• 3:09
  SPEAKER_00: A true outflow enhancer should show extra pressure drop, especially in the daytime trough, or reduce the difference between peak and trough pressures, reflecting improved drainage.
• 3:19
  SPEAKER_00: In some trials, outflow facility or drainage imaging, e.g., canal angiography, may also be assessed.
• 3:26
  SPEAKER_00: Safety endpoints monitor vision and eye examination.
• 3:29
  SPEAKER_00: Safety considerations.
• 3:31
  SPEAKER_00: Outflow drugs commonly cause ocular redness, conjunctival hyperemia, and light sensitivity because they act on blood vessels and nearby tissues.
• 3:40
  SPEAKER_00: In pooled studies of natars, a rock inhibitor, over half of patients had mild, transient red eye.
• 3:46
  SPEAKER_00: This is expected and usually tolerable.
• 3:49
  SPEAKER_00: MiG's devices or lasers carry risks of mild bleeding, hyphema, and short-term pressure spikes, so protocols watch IOP closely after surgery.
• 3:58
  SPEAKER_00: Systemic side effects are generally minimal, but care is taken to avoid very low pressure hypotenuse in the first weeks.
• 4:06
  SPEAKER_00: All trial protocols include monitoring for inflammation or infection.
• 4:10
  SPEAKER_00: Inflow suppressors, what it is.
• 4:13
  SPEAKER_00: These approaches reduce aqueous humor production by the ciliary body, the tissue that makes fluid.
• 4:18
  SPEAKER_00: Traditional inflow suppressors include beta blockers and carbonic anhydrase inhibitors.
• 4:24
  SPEAKER_00: New strategies under study include innovative delivery systems, e.g., implants or injections of these or similar agents to improve duration and compliance.
• 4:33
  SPEAKER_00: Rationale, preclinical, and early data.
• 4:36
  SPEAKER_00: Laboratory research confirms that slowing ciliary fluid generation lowers pressure.
• 4:41
  SPEAKER_00: For example, continuous release formulations of timolol, a beta blocker, placed inside the eye, have shown stable IOP lowering in animal models and early human tests.
• 4:52
  SPEAKER_00: Sustained release implants maintain effective drug levels far longer than a drop, overcoming the problem of poor adherence.
• 4:59
  SPEAKER_00: No novel molecular inflow target has emerged recently beyond the known pathways, so most innovation is in delivery, sustained release, or combination approaches.
• 5:09
  SPEAKER_00: Earlier trial results.
• 5:11
  SPEAKER_00: ID Pharma's Timo D implant is a proof of concept.
• 5:14
  SPEAKER_00: In a phase one human study, a tiny biodegradable implant releasing TMOLAL was safely inserted, often at cataract surgery, and produced a consistent modest IOP reduction over months.
• 5:25
  SPEAKER_00: The follow-on trial results showed that patients could maintain lower pressures with little need for extra drops.
• 5:31
  SPEAKER_00: Other devices, e.g.
• 5:33
  SPEAKER_00: slow-released dorzolamide rings or micropumps, are in early phases.
• 5:37
  SPEAKER_00: So far, early human data support that these implants safely suppress fluid production as intended.
• 5:44
  SPEAKER_00: Primary endpoints.
• 5:45
  SPEAKER_00: The main efficacy measure is again mean IOP reduction over time.
• 5:49
  SPEAKER_00: Some studies look at the percentage of patients maintaining target IOP at 6 or 12 months without additional medication.
• 5:57
  SPEAKER_00: In trials combining an inflow implant at cataract surgery, the endpoint might be post-surgical IOP versus control.
• 6:04
  SPEAKER_00: Diurnal IOP could also be measured, similar to outflow studies.
• 6:09
  SPEAKER_00: If the implant is meant to last a year, researchers may focus on IOP at 6 and 12 months as primary data points.
• 6:16
  SPEAKER_00: Safety endpoints include corneal and anterior segment exams to check the implant placement and heart respiratory monitoring to catch any systemic drug absorption, particularly for beta blockers.
• 6:28
  SPEAKER_00: Safety considerations.
• 6:30
  SPEAKER_00: Because these agents act on the eye's fluid pumps, they can rarely affect the whole body if absorbed.
• 6:36
  SPEAKER_00: Protocols watch for cardiovascular effects, e.g., slowing of heart rate by beta blockers.
• 6:42
  SPEAKER_00: Local side effects include eye irritation or blurred vision, which are tracked.
• 6:47
  SPEAKER_00: Stinging or surface irritation from the implant is also possible.
• 6:50
  SPEAKER_00: Trials include slit lamp exams at each visit.
• 6:53
  SPEAKER_00: Importantly, sudden device failure, e.g., implant migration or breakage, is monitored.
• 6:59
  SPEAKER_00: So far, published trials report good tolerability with these sustained release devices.
• 7:04
  SPEAKER_00: Antifibrotics, anti-scarring agents.
• 7:07
  SPEAKER_00: What it is?
• 7:08
  SPEAKER_00: Antifibrotic therapies are given around the time of glaucoma surgery or even with some MIGs to prevent scar tissue from closing the new drainage pathway.
• 7:17
  SPEAKER_00: Standard drugs like mitomycin C MMC are toxic cytotoxins.
• 7:22
  SPEAKER_00: Newer agents aim to block scarring in a more precise way, ideally with fewer side effects.
• 7:27
  SPEAKER_00: For example, csiRNA molecules that silence fibrosis genes like MRTFB are being tested.
• 7:33
  SPEAKER_00: Rationale Preclinical and Early Data.
• 7:35
  SPEAKER_00: Scarring of the conjunctival bleb or drainage channel is the main cause of surgery failure.
• 7:40
  SPEAKER_00: Researchers have identified cellular pathways, like the MRTF transcription pathway that drive fibroblast proliferation.
• 7:48
  SPEAKER_00: In lab models, blocking MRTF prevents scar formation.
• 7:52
  SPEAKER_00: One report found that a novel MRTF inhibitor prevented scar tissue as effectively as MMC in a rabbit eye model.
• 7:59
  SPEAKER_00: Similarly, early studies of an sIRNA targeting MRTF-B ECP-105 in animal glaucoma filtration models showed a 30% decrease in scar markers.
• 8:09
  SPEAKER_00: These studies provide strong preclinical evidence that targeted antifibrotics can reduce post-surgical scarring without widespread cell death.
• 8:17
  SPEAKER_00: Earlier trial results.
• 8:19
  SPEAKER_00: Most antifibrotic approaches are still preclinical, but a few human trials have started.
• 8:24
  SPEAKER_00: For example, new small molecules or antibody fragments against TGF beta, another fibrosis factor, are in early safety trials.
• 8:32
  SPEAKER_00: A clinical trial in Asia used a new IOP lowering drop with anti-scarring activity and reported less conjunctival fibrosis at six months, an early human hint.
• 8:43
  SPEAKER_00: These emerging data suggest that antifibrotics can improve surgical outcomes without the high complication rates of older drugs.
• 8:51
  SPEAKER_00: Primary endpoints.
• 8:53
  SPEAKER_00: Trials tend to use surgery success rates as endpoints.
• 8:56
  SPEAKER_00: This might mean the proportion of patients maintaining open filtration, bleb with controlled IOP at 6 or 12 months without additional medication.
• 9:05
  SPEAKER_00: In some studies, success is defined by IOP target, e.g.
• 9:09
  SPEAKER_00: 15 mm hergrams, or by the need for drop-free control.
• 9:13
  SPEAKER_00: Imaging of the bleb via OCT or slit lamp grating is often a secondary endpoint to quantify scar tissue.
• 9:20
  SPEAKER_00: Some trials also measure the rate of reintervention, need to reopen or revise the bleb as a proxy for fibrosis.
• 9:26
  SPEAKER_00: In all cases, protocols carefully monitor hypotony, too low IOP, and bleb leaks, since aggressive antifibrosis can overbalance drainage.
• 9:35
  SPEAKER_00: Safety considerations.
• 9:36
  SPEAKER_00: Classic antifibrotics like MMC reduce scarring but cause complications, leaking blebs, flat, cataract-inducing hypotony, infection risk, and endophthalmitis.
• 9:46
  SPEAKER_00: Newer agents aim to avoid these.
• 9:48
  SPEAKER_00: Trial protocols include frequent exams for leaks, low pressure, and retinal evaluation.
• 9:54
  SPEAKER_00: If cRNA or small molecule inhibitors are used, systemic exposure is minimal, they are injected locally, but local inflammation or allergies are watched for.
• 10:03
  SPEAKER_00: Safety protocols also require measuring endothelial cell health and vision, since corneal damage can occur if the drug spreads.
• 10:11
  SPEAKER_00: In published animal models, MRTF inhibitors did not show extra toxicity, making them a promising, safer class.
• 10:19
  SPEAKER_00: Neuroprotective strategies what it is.
• 10:21
  SPEAKER_00: Neuroprotective treatments aim to preserve optic nerve fibers and retinal ganglion cells independent of IOP.
• 10:28
  SPEAKER_00: This can include metabolic therapies, growth factors, or neural signaling modifiers.
• 10:33
  SPEAKER_00: Examples in 2026 trials include high-dose vitamin B3, nicotinamide, diabetes drugs, GLP1 agonists like semaglutide, L-type calcium channel blockers, and novel neurotransmitter modulators.
• 10:46
  SPEAKER_00: The idea is to boost the eye's resistance to glaucoma damage, so even if some pressure remains, the nerve survives.
• 10:53
  SPEAKER_00: Rationale Preclinical and Early Data.
• 10:56
  SPEAKER_00: Lab studies repeatedly show that interventions like nicotinamide, vitamin B3, or GLP1 drugs improve retinal neuron health in glaucoma models.
• 11:05
  SPEAKER_00: For instance, one RAT study found daily semaglutide delayed pressure rise and protected retinal neurons in ocular hypertensive eyes.
• 11:13
  SPEAKER_00: Similarly, nicotinamide, a precursor of cellular energy cofactor NAD, restored inner retinal function in a small human trial of glaucoma patients.
• 11:23
  SPEAKER_00: Another drug, BL1107, a new alpha-2 agonist, is thought to enhance nerve cell survival.
• 11:29
  SPEAKER_00: Early human data suggest BL107 improves visual field sensitivity beyond what TML achieves.
• 11:36
  SPEAKER_00: These findings gave rise to neuroprotection trials in humans.
• 11:40
  SPEAKER_00: Earlier trial results.
• 11:42
  SPEAKER_00: So far, dedicated neuroprotection trials have been small or ongoing.
• 11:46
  SPEAKER_00: The perfuse endothelin antagonist, PR001, see next section, was the first to show better visual field and nerve imaging results in treated glaucoma patients.
• 11:56
  SPEAKER_00: A few other pilot studies, like mimantine in the past or bromonidine's neuroeffects, gave mixed results, so current trials often combine neuroprotectives with IOP lowering.
• 12:07
  SPEAKER_00: Notably, a phase two of high-dose nicotinamide reported improved inner retinal function on electrophysiology, and longer-term nicotinamide studies are now enrolling.
• 12:18
  SPEAKER_00: These suggest human eyes can respond to metabolic neural support in line with the protective hypothesis.
• 12:24
  SPEAKER_00: Primary endpoints.
• 12:26
  SPEAKER_00: Neuroprotection trials cannot rely solely on short-term IOP change.
• 12:30
  SPEAKER_00: They focus on measures of nerve structure and function over time.
• 12:34
  SPEAKER_00: Primary endpoints often include rate of visual field progression and OCT retinal nerve fiber layer RNFL thickness.
• 12:41
  SPEAKER_00: For example, the perfuse trial measured visual field sensitivity and OCT RNFL thickness at 6 and 12 months.
• 12:49
  SPEAKER_00: A successful neuroprotective agent might be expected to slow thinning of the RNFL or reduce the loss of visual field sensitivity over time.
• 12:57
  SPEAKER_00: Some trials also use electrophysiologic tests, pattern ERG, or optic nerve head blood flow as endpoints.
• 13:03
  SPEAKER_00: Because nerve damage progresses slowly, typical study durations are 1 to 2 years.
• 13:09
  SPEAKER_00: Safety considerations.
• 13:11
  SPEAKER_00: These agents are systemic or ophthalmic, so their side effects vary by class.
• 13:16
  SPEAKER_00: High dose vitamins, like nicotinamide, can cause flushing or stomach upset.
• 13:20
  SPEAKER_00: Trials monitor liver function for metabolic drugs.
• 13:23
  SPEAKER_00: Neurotrophic factors delivered in the eye, e.g., ciliary neurotrophic factor implants, require surgery, so injection-related issues, infection, retinal detachment, are watched.
• 13:34
  SPEAKER_00: Blended agents like BL1107 are topical and generally well tolerated.
• 13:39
  SPEAKER_00: Trials include checks of blood pressure or heart rate in case systemic absorption occurs.
• 13:44
  SPEAKER_00: A special concern is that some neuroactive drugs could affect retinal blood vessels or intraocular inflammation, so protocols include regular slit lamp exams and retinal imaging.
• 13:55
  SPEAKER_00: In published trials, e.g.
• 13:57
  SPEAKER_00: perfuse, the neuroprotective implant was reported safe and well tolerated during six months, but long-term monitoring remains critical.
• 14:05
  SPEAKER_00: Vascular modulators.
• 14:07
  SPEAKER_00: What it is.
• 14:08
  SPEAKER_00: These therapies target the blood flow to the optic nerve head, aiming to improve circulation in glaucoma disease.
• 14:15
  SPEAKER_00: Glaucoma is linked not only to pressure but also vascular factors.
• 14:19
  SPEAKER_00: Poor perfusion may contribute to nerve damage.
• 14:22
  SPEAKER_00: Vascular modulators include drugs that dilate ocular blood vessels or block vasoconstrictors.
• 14:28
  SPEAKER_00: A leading example is an endothin receptor antagonist implant, Pier01 by Perfuse, designed to increase optic nerve blood flow.
• 14:37
  SPEAKER_00: Rationale, preclinical and early data.
• 14:40
  SPEAKER_00: Eyes with glaucoma often show reduced optic nerve perfusion.
• 14:44
  SPEAKER_00: Endothelin is a natural molecule that constricts blood vessels.
• 14:48
  SPEAKER_00: It is elevated in glaucoma.
• 14:49
  SPEAKER_00: In animal glaucoma models, blocking endothelin locally increases optic nerve blood flow and can protect nerve cells from dying.
• 14:58
  SPEAKER_00: In early trials of PR001, treated eyes showed about a 10% increase in nerve blood flow compared to untreated eyes, which correlated with better visual field stability.
• 15:09
  SPEAKER_00: These results provide a strong rationale that improving perfusion can be neuroprotective.
• 15:14
  SPEAKER_00: Earlier trial results.
• 15:16
  SPEAKER_00: In a Phase 2A human study of PR001, patients received one intravitreal implant and continued their usual IOP lowering drops.
• 15:25
  SPEAKER_00: At six months, the PR001 group had small but consistent improvements in visual field sensitivity and OCT RNFL thickness, whereas control eyes tended to worsen.
• 15:35
  SPEAKER_00: These outcomes go beyond pressure lowering, suggesting a true effect on nerve health.
• 15:41
  SPEAKER_00: Importantly, the trial reported that the implant raised blood flow as intended, validating the mechanism.
• 15:47
  SPEAKER_00: Such results are encouraging enough that a larger phase 2B trial is planned.
• 15:52
  SPEAKER_00: Primary endpoints.
• 15:54
  SPEAKER_00: Vascular trials often use endpoints similar to neuroprotection trials, since the goal is functional preservation.
• 16:01
  SPEAKER_00: Key measures are optic nerve imaging and visual fields.
• 16:04
  SPEAKER_00: The perfuse study explicitly included visual field change and OCT RNFL thickness as registrable outcomes.
• 16:12
  SPEAKER_00: Because the mechanism does not primarily lower IOP, pressure was a secondary measure.
• 16:17
  SPEAKER_00: Some vascular trials also directly measure blood flow using OCT angiography or Doppler as a proof-of-mechanism endpoint.
• 16:24
  SPEAKER_00: In general, expected proof-of-concept endpoints for this class are slowed RNFL loss or stabilized visual field over time.
• 16:33
  SPEAKER_00: Safety considerations.
• 16:35
  SPEAKER_00: Most vascular modulators are administered by injection or implant to act inside the eye.
• 16:40
  SPEAKER_00: Therefore, they carry the usual risks of intraocular procedures, inflammation, infection, endophthalmitis, bleeding, or retinal detachment.
• 16:48
  SPEAKER_00: Protocols require careful follow-up exams and retinal imaging after injection.
• 16:53
  SPEAKER_00: Another concern is systemic effect.
• 16:55
  SPEAKER_00: Blocking endothelin systemically could affect blood pressure, so patients' vitals are monitored.
• 17:01
  SPEAKER_00: In the reported glaucoma implant trial, PRR01 was safe and well tolerated through six months, with no serious ocular events attributable to the device.
• 17:11
  SPEAKER_00: Still, long-term effects on retinal vessels and perfusion are watched closely.
• 17:16
  SPEAKER_00: Conclusion: In April 2026, a wave of clinical trials is exploring new therapeutic mechanisms for glaucoma beyond simple IOP reduction.
• 17:26
  SPEAKER_00: These include drugs and devices that enhance natural drainage outflow channels, blockers of aqueous production delivered in long-acting forms, targeted anti-scarring agents, and innovative neuro and vascular protective strategies.
• 17:40
  SPEAKER_00: Each approach is grounded in sound laboratory evidence, animal or cellular models, and increasingly promising human data.
• 17:48
  SPEAKER_00: Trials have chosen endpoints that match the mechanism.
• 17:51
  SPEAKER_00: Outflow enhancers focus on IOP curves and drainage metrics.
• 17:55
  SPEAKER_00: Antifibrotic studies focus on surgical success and need for reoperations, and neurovascular agents focus on nerve imaging, OCTRNFL, and visual field preservation.
• 18:07
  SPEAKER_00: Safety is carefully monitored within each class.
• 18:10
  SPEAKER_00: For example, outflow drugs are checked for eye redness and hypotony, antifibrotics for leaks and infections, and injection therapies for inflammation.
• 18:19
  SPEAKER_00: These novel trials hold real promise.
• 18:22
  SPEAKER_00: If successful, they could reshape glaucoma care by offering patients better pressure control with fewer daily drops, longer lasting treatments, and even protection of vision beyond pressure effects.
• 18:35
  SPEAKER_00: Patients should discuss with their doctors the possibility of participating in such trials or trying new therapies when approved.
• 18:42
  SPEAKER_00: The future of glaucoma treatment is moving toward multi-pronged care, combining safer scarring prevention, improved drainage, and direct nerve protection to keep vision safe.
• 18:53
  SPEAKER_00: All links to sources are available in the text version of this article.
• 18:56
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 19:00
  SPEAKER_00: Thanks for listening.
• 19:02
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.